-
Product Insights
New![]()
Net Present Value Model: IO Biotech Inc’s (IO-102 + IO-103)
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Solid Tumor Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Ureter Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Ureter Cancer Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Bladder Cancer Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Urethral Cancer Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Lung Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Lung Adenocarcinoma Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Metastatic Melanoma Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Kidney Cancer (Renal Cell Cancer) Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Non-Small Cell Lung Cancer Drug Details: PD-L1/IDO (IO102/IO103) peptide vaccine is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.